History

Thymosin beta-4 emerged from Allan Goldstein's work on thymic extracts: the crude "thymosin fraction 5" was isolated from calf thymus in 1972, and in 1981 Low, Hu, and Goldstein published the complete amino-acid sequence of the bovine peptide (PNAS 78:1162-1166) — 43 residues with a blocked N-terminus. First thought to be a thymic hormone, it was later recognized as the main actin-sequestering protein in many cells. RegeneRx and partners ran ophthalmic, dermal, and cardiac programs from the 2000s onward; the WHO assigned the name "timbetasin" in 2018. No approvals have followed.

Thymosin beta-4 is unusual among “research peptides” because it has actually been through registered, peer-reviewed human trials. That is the honest selling point — and also where the story gets complicated, because the best-studied use has now missed its primary endpoint in two separate Phase 3 trials. It is also routinely confused with the gray-market fragment TB-500, which is a different molecule with far weaker evidence.

What it is

Thymosin beta-4 (Tβ4) is a naturally occurring protein of 43 amino acids (about 4,982 daltons) found in nearly every human cell. It is encoded by the gene TMSB4X and is intrinsically disordered when floating free in solution, with an acetyl-blocked end.

Its main known job inside cells is actin sequestration. Actin is a building block of the cell’s internal skeleton, and it exists either as free monomers (G-actin) or assembled filaments (F-actin). Tβ4 binds free actin monomers one-to-one, holding a reserve pool and preventing it from spontaneously assembling into filaments. Crystallography shows the peptide capping both ends of the actin monomer to block it from joining a filament; a short stretch called the LKKTET motif is the classic binding signature, though nearly the whole peptide touches actin.

Beyond actin, secreted Tβ4 is reported to promote cell migration, blood-vessel formation, and anti-inflammatory and anti-scarring effects. These “moonlighting” activities are the basis for the wound-healing and tissue-repair hypotheses, and they are mostly worked out in cells and animals rather than in people.

The claims

Legitimate drug development has focused on a narrow set of indications: healing the surface of the eye (neurotrophic keratopathy and dry eye disease) via eye drops, and skin and wound healing via a topical gel. An injectable version was aimed at heart-attack and tissue repair but stalled.

The gray-market and off-label claims are much broader — and are almost always attached to the TB-500 fragment, not the full protein. Sellers and forums promote faster healing of tendon, ligament, and muscle injuries, reduced inflammation, faster recovery, anti-aging, and hair growth. These are extrapolations from animal data and mechanism, not from human outcome trials.

A critical point for readers: TB-500 is not full-length Tβ4. TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ, residues 17–23) containing the actin-binding motif. The human trials below tested the full 43-amino-acid protein (timbetasin), not the fragment sold online. Vendors frequently cite these trials as if they validate TB-500; they do not. A separate fragment, Ac-SDKP (goralatide), is yet another distinct molecule and also not TB-500.

The evidence

Safety / Phase 1. The cornerstone human safety data comes from Ruff and colleagues (2010), a randomized, placebo-controlled Phase 1 trial of intravenous synthetic Tβ4 in healthy volunteers: four groups of ten, single doses of 42, 140, 420, and 1,260 mg, followed by daily dosing for 14 days. It was well tolerated, with no dose-limiting toxicities and no serious adverse events, and dose-proportional pharmacokinetics. A separate first-in-human trial of recombinant Tβ4 in Chinese volunteers (Wang 2021) tested far smaller intravenous doses (micrograms per kilogram) with daily dosing for 10 days, again finding only mild-to-moderate adverse events and no dose-limiting toxicity. Both were small, short, and run by or affiliated with the sponsors.

Eye surface — the best efficacy signal, still preliminary. A Phase 2 dry-eye trial (Sosne 2015) of the eye-drop formulation reported reductions in ocular discomfort and corneal staining — but enrolled only nine patients, making it hypothesis-generating at best. The Phase 3 dry-eye program (the ARISE trials) was mixed: ARISE-3 did not meet its pre-specified co-primary endpoints, with only a secondary symptom (ocular grittiness) reaching statistical significance, and the results came mainly through company press releases rather than full peer-reviewed papers.

The neurotrophic keratopathy program is the most-cited. The published Phase 3 (SEER-1, 2022) is the source of the frequently quoted “60% vs 12.5%” healing figure — but that was a missed primary endpoint (p=0.0656), in a trial terminated early at just 18 of a planned 46 patients because the rare disease enrolled slowly. A day-43 secondary endpoint did reach significance. A separate European Phase 3 (SEER-3) also missed its primary endpoint, which the sponsor attributed to a stronger-than-expected placebo response. A US trial (SEER-2) began enrolling in 2023.

Wound / dermal. A Phase 2 trial in venous stasis ulcers (Guarnera 2010) was run as a placebo-controlled dose-escalation study across European sites. A trial in the skin-blistering disease epidermolysis bullosa was terminated around 2012 for lack of enrollment.

Heart and stroke — human data essentially absent. The injectable heart-attack trial was withdrawn and never initiated. Animal work in the 2000s (notably Nature papers in 2004 and 2007) reported that Tβ4 could mobilize heart-surface progenitor cells and promote new blood vessels, but later work (Zhou 2011) found that giving Tβ4 after a heart attack increased capillary density without reprogramming those cells into new heart muscle — making the regeneration claim disputed in the clinically relevant post-injury setting rather than simply confirmed. A widely cited stroke “dose-response” paper is a study in rats, not humans — a genuine citation trap. No completed human stroke or cardiac efficacy trial exists.

What’s missing. There is no positive, replicated, adequately powered Phase 3 for any indication; the strongest candidate, neurotrophic keratopathy, has missed its primary endpoint in two Phase 3 trials. There are no independent (non-sponsor) confirmatory efficacy trials, no long-term safety data, and essentially no dedicated human efficacy data for the TB-500 fragment that most people actually buy.

Safety and side effects

Within the trials, short-term human safety looks favorable. Intravenous Tβ4 up to 1,260 mg (single dose and 14-day) was well tolerated with no dose-limiting toxicities or serious adverse events; the recombinant version showed only mild-to-moderate effects; and the topical eye drops were consistently described as safe and well tolerated, with adverse-event rates similar to placebo.

The limitations matter as much as the reassurance. These data come from small samples, short durations, narrowly selected populations, and mostly sponsor-run studies. There is no long-term human safety data, and no data in children or pregnancy. A theoretical concern — that a factor promoting blood-vessel growth, cell migration, and cell survival could in principle also favor tumor growth — has not been characterized in humans; it is an open question, not a documented harm. Separately, gray-market products (typically TB-500) carry real-world risks of mislabeling, impurities, and contamination that are independent of the molecule itself. Nothing here is medical advice.

Legal and regulatory status

Thymosin beta-4 is not approved for any indication in the US, EU, UK, or Australia. The FDA granted it orphan-drug designation for neurotrophic keratopathy in 2013, but an orphan designation is not an approval. A 2011 clinical hold on the injectable heart-attack program was due to manufacturing (cGMP) non-compliance at a contract manufacturer, not a safety problem; that cardiac trial was later withdrawn. China’s recombinant version is in clinical trials with no confirmed regulatory approval.

For US pharmacy compounding, the status is unsettled and has been volatile — check the current FDA 503A bulk drug substances list rather than any vendor’s claim.

In sport, Tβ4 and its derivatives are prohibited at all times by WADA under Section S2 (peptide hormones, growth factors, and related substances), a ban effective from the 2012 Prohibited List; it featured in high-profile Australian doping cases. Athletes should confirm the current year’s list wording directly. Products sold online (mostly as TB-500) are labeled “research use only,” are not pharmaceutical grade, and have no legal route for personal therapeutic use in the US.

Bottom line

Thymosin beta-4 is a real molecule with real, registered human trials — which sets it apart from most peptides marketed for “healing.” But the human evidence is thin and uneven: the safety record is short-term and sponsor-run, the eye-surface program has missed its primary endpoints in two Phase 3 trials, and the heart and stroke story rests on animal work that is disputed for the situation that matters. There is essentially no human efficacy data for the TB-500 fragment most buyers actually use. Treat the broad recovery and anti-aging claims as unproven.

Evidence grade: Preliminary human.

Thymosin Beta-4: Real Human Trials, But the Best Indication Has Missed Two Phase 3s